Ovarian cancer is not one single disease. The term covers several cancers that begin in or involve the ovaries, and modern oncology often groups the most common epithelial ovarian cancers together with fallopian tube and primary peritoneal cancers because they arise from similar tissues and are treated in similar ways. Research also suggests that many high-grade serous cancers previously labeled “ovarian” may actually begin in the fimbrial end of the fallopian tube. Ovarian cancer can be difficult to detect early because symptoms are often vague and there is no proven routine screening test for average-risk, asymptomatic women. In the United States, the American Cancer Society estimates that about 21,010 women will be diagnosed with ovarian cancer in 2026 and about 12,450 will die from it. This guide explains common symptoms, major risk factors, hereditary syndromes, how diagnosis and staging work, why CA-125 and ultrasound are not recommended as population screening tests, and the main treatment approaches. It is general educational information, not personal medical advice. This article focuses on ovarian cancer symptoms and treatment, while also explaining risk factors, diagnosis, screening limits, and prognosis.
Understanding Ovarian Cancer and Its Symptoms
The National Cancer Institute — Ovarian Cancer Information explains that ovarian, fallopian-tube, and primary peritoneal cancers are closely related diseases that are often discussed together because of shared biology and treatment approaches. The ovaries are two reproductive organs located on either side of the uterus. They produce eggs and hormones. Ovarian tumors can arise from different cell types. The major categories include: Epithelial tumors.; Germ cell tumors.; Stromal tumors.; Borderline or low malignant potential tumors.. Epithelial ovarian cancers are the most common adult ovarian cancers. Ovarian, Fallopian Tube and Primary Peritoneal Cancer The National Cancer Institute groups epithelial ovarian, fallopian tube, and primary peritoneal cancers together because they often arise from related Müllerian tissue and have similar treatment. This is important because “ovarian cancer” may actually originate in a nearby fallopian tube even when the disease is first detected around the ovary.
Common Symptoms Ovarian cancer may not cause obvious early symptoms. When symptoms occur, they can resemble common digestive, urinary, or gynecologic problems. NCI lists symptoms including: Abdominal or pelvic pain.; Abdominal swelling or pressure.; Bloating.; Difficulty eating.; Feeling full quickly.; Urinary urgency or frequency.; Constipation or other gastrointestinal changes.; A pelvic mass in some cases.. These symptoms usually have causes other than cancer. The concern increases when they are new, persistent, worsening, or unexplained. When Should Symptoms Be Evaluated? Persistent abdominal or pelvic symptoms should be discussed with a healthcare professional, especially when they represent a clear change from normal. Urgent evaluation may be needed for severe pain, major abdominal swelling, difficulty breathing, heavy bleeding, or other acute symptoms. No symptom checklist can diagnose ovarian cancer. Why Ovarian Cancer Is Often Diagnosed Later The ovaries are located deep in the pelvis, and early tumors may not cause distinctive symptoms. By the time symptoms become obvious, some epithelial cancers have already spread within the abdomen or pelvis. NCI notes that ovarian epithelial, fallopian tube, and primary peritoneal cancers are often advanced at diagnosis. Risk Factors Risk is influenced by age, genetics, reproductive history, and other factors. Important risk factors include:
Increasing age.; Family history of ovarian cancer.; Inherited BRCA1 or BRCA2 variants.; Lynch syndrome and some other hereditary cancer syndromes.; Personal history of certain related cancers.. Having a risk factor does not mean a person will develop cancer. Age Ovarian cancer mainly affects older women. The American Cancer Society reports that about half of women diagnosed are age 63 or older. Some less common ovarian tumor types occur in younger patients. Family History A family history of ovarian, breast, pancreatic, prostate, colorectal, or related cancers can sometimes signal a hereditary cancer syndrome. The pattern matters more than a single isolated case. People with concerning family histories can discuss genetic counseling with a qualified clinician. BRCA1 and BRCA2 Inherited harmful variants in BRCA1 or BRCA2 can substantially increase ovarian and breast cancer risk. Genetic testing is not simply a consumer curiosity. Results can affect: Screening for other cancers.; Risk-reducing surgery decisions.; Treatment choices if cancer develops.; Testing recommendations for relatives.. Testing decisions are best made with appropriate counseling. Lynch Syndrome Lynch syndrome is another inherited condition that can increase the risk of several cancers, including colorectal, endometrial, and ovarian cancers. Family histories involving multiple related cancers at younger ages may warrant genetic evaluation. Does Pregnancy History Affect Risk? Some reproductive factors are associated with ovarian cancer risk. Factors that reduce the number of lifetime ovulations, such as pregnancies and oral contraceptive use, have been associated with lower risk of some epithelial ovarian cancers. These associations should not be interpreted as personal treatment recommendations.
Risk, Genetics and Why Routine Screening Is Different
The USPSTF — Ovarian Cancer Screening Recommendation recommends against routine screening in asymptomatic women who are not known to have a high-risk hereditary cancer syndrome because available screening methods have not shown a mortality benefit and can lead to harms from false-positive results and unnecessary procedures. For average-risk women without symptoms, there is currently no recommended routine population screening program equivalent to mammography or cervical screening. The U.S. Preventive Services Task Force recommends against screening asymptomatic women who do not have a known high-risk hereditary cancer syndrome. Why Routine Screening Is Not Recommended Screening needs to do more than find abnormalities. It needs to improve health outcomes while minimizing harm. Large studies of CA-125 blood testing and transvaginal ultrasound in average-risk women did not show a reduction in ovarian-cancer mortality. False-positive results can lead to: Repeat testing.; Anxiety.; Invasive surgery.; Surgical complications..
That is why screening tests that sound intuitive can still do more harm than good in low-risk populations. What Is CA-125? CA-125 is a protein that can be elevated in the blood of some people with ovarian cancer. However, CA-125 is not specific to ovarian cancer. It can also be elevated by benign conditions. Some ovarian cancers do not produce high CA-125 levels, particularly at early stages. CA-125 can be useful in specific diagnostic and treatment-monitoring contexts, but it is not recommended as a stand-alone screening test for average-risk asymptomatic women. What Is Transvaginal Ultrasound? Transvaginal ultrasound uses sound waves from a probe placed in the vagina to create images of pelvic organs. It can help evaluate an ovarian mass or unexplained symptoms. Like CA-125, it has not been shown to reduce mortality when used as routine population screening in average-risk women. What Happens When Ovarian Cancer Is Suspected? Evaluation can include: Medical history.; Pelvic examination.; Imaging.; Blood tests.; Referral to a gynecologic oncologist.. Definitive diagnosis generally requires examination of tumor tissue. Imaging Imaging may include ultrasound, CT, MRI, or other tests depending on the situation. Imaging helps assess: The size of a mass.; Its characteristics.; Possible spread.; Surgical planning.. Staging Ovarian cancer is staged from I to IV. In simplified terms: Stage I: disease limited to the ovaries or fallopian tubes.; Stage II: spread within the pelvis.; Stage III: spread outside the pelvis within the abdomen and/or to certain lymph nodes.; Stage IV: distant spread outside the abdomen or to certain organs.. Exact staging uses detailed surgical and pathological criteria. Why Stage Matters Stage affects prognosis and treatment planning. Early-stage disease may sometimes be treated with surgery alone or surgery followed by chemotherapy, depending on tumor type and grade. Advanced disease often requires a combination of surgery and systemic treatment.
Diagnosis, Staging and Current Treatment
The National Cancer Institute — Ovarian Epithelial, Fallopian Tube and Primary Peritoneal Cancer Treatment outlines how surgery, platinum-based chemotherapy, targeted therapies, maintenance strategies, and clinical trials may be used depending on tumor type, stage, molecular features, prior treatment, and the patient’s overall health. Surgery is central to treatment for many epithelial ovarian cancers. Depending on stage, age, fertility goals, and tumor type, surgery can involve: Removal of one or both ovaries and fallopian tubes.; Hysterectomy.; Removal of the omentum.; Biopsy or removal of lymph nodes or other tissues.; Debulking of visible cancer.. When possible, surgery by a gynecologic oncologist is important because ovarian cancer requires specialized staging and cytoreduction. Debulking Surgery Debulking means removing as much visible tumor as possible. For advanced ovarian cancer, the amount of residual disease after surgery can affect outcome. In some cases chemotherapy is given before surgery when immediate extensive surgery is not considered the best first step. Chemotherapy Chemotherapy is commonly used for epithelial ovarian cancer. Platinum-based chemotherapy is a major component of standard treatment for many patients. The exact regimen depends on cancer subtype, stage, health status, prior treatment, and other factors. Targeted Therapy Targeted treatments can act on specific biological pathways involved in cancer. NCI lists agents such as bevacizumab and PARP inhibitors among treatment options in selected situations.
PARP Inhibitors PARP inhibitors interfere with a DNA-repair pathway. They can be particularly relevant in tumors with BRCA mutations or other forms of homologous recombination deficiency, although exact indications have evolved as evidence and regulatory approvals change. Patients should rely on current oncology guidance rather than older generalized descriptions of who should receive these drugs. Clinical Trials Clinical trials test new treatments, combinations, sequences, and supportive-care strategies. NCI maintains information about cancer clinical trials. A trial can be appropriate at different stages of disease and is not necessarily a “last resort.” Fertility Preservation Some younger patients with selected early-stage tumors may be candidates for fertility-sparing treatment. This requires careful specialist evaluation because preserving an ovary or the uterus is not safe for every cancer type or stage. Risk-Reducing Surgery People with certain high-risk hereditary mutations may consider removal of the fallopian tubes and ovaries after childbearing, according to individualized specialist guidance. NCI notes that risk-reducing surgery can substantially reduce ovarian cancer risk in high-risk women. Why the Fallopian Tubes Matter in Prevention Evidence that many high-grade serous cancers may originate in the fallopian tubes has changed scientific thinking about prevention.
Researchers continue to study whether removing fallopian tubes while delaying ovary removal can reduce risk while minimizing early menopause in some high-risk situations. This remains an area for specialist guidance and research. Can Lifestyle Prevent Ovarian Cancer? There is no lifestyle change that guarantees prevention. Maintaining overall health is beneficial, but genetic and reproductive factors play important roles in ovarian cancer risk. People at unusually high hereditary risk need medical risk-management strategies rather than relying only on diet or exercise. Ovarian Cysts vs. Ovarian Cancer Ovarian cysts are common and most are not cancer. Risk assessment depends on: Age.; Menopausal status.; Ultrasound appearance.; Symptoms.; Size and change over time.; Family history.. An ovarian cyst should not automatically be described as a tumor or cancer. Survival Statistics Survival varies greatly by stage, tumor type, age, response to treatment, and other factors. Population statistics cannot predict exactly what will happen to an individual patient. Personal prognosis should be discussed with the oncology team using current pathology and staging information.
Prognosis, Survival Statistics and Questions After Diagnosis
The American Cancer Society — Ovarian Cancer Statistics 2026 estimates about 21,010 new U.S. diagnoses and about 12,450 deaths from ovarian cancer in 2026. Population statistics describe groups rather than predicting the course of any one person’s cancer, so stage, tumor subtype, genetics, treatment response, age, and overall health remain essential to individual prognosis. The American Cancer Society estimates that in 2026: About 21,010 women in the United States will receive a new ovarian cancer diagnosis.; About 12,450 women will die from ovarian cancer.; Lifetime risk of developing ovarian cancer is about 1 in 91.. Questions to Ask After a Diagnosis Useful questions can include: What exact type of ovarian cancer is this?; What stage and grade is it?; Was molecular or genetic testing performed?; Should I see a gynecologic oncologist?; Is surgery recommended first?; What are the goals and side effects of chemotherapy?; Are targeted therapies relevant?; Are there clinical trials I should consider?.
Conclusion
Ovarian cancer remains challenging because it can develop without distinctive early symptoms and because routine screening has not been shown to reduce mortality in average-risk asymptomatic women. The most important practical points are to take persistent new symptoms seriously, understand family history, and seek genetic counseling when hereditary risk may be present. For people diagnosed with ovarian cancer, treatment planning depends on the exact tumor type, stage, molecular features, health status, and surgical options. Modern treatment goes beyond a simple surgery-plus-chemotherapy model. Targeted therapies and genetic information increasingly influence care, while specialized gynecologic oncology remains central. This article is educational. Anyone with persistent symptoms, a concerning family history, an abnormal ovarian mass, or a cancer diagnosis should discuss the situation with an appropriate healthcare professional.